Dual Antithrombotic Therapy With Dabigatran vs Triple Therapy With Warfarin After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation With or Without a Proton Pump Inhibitor (A Prospectively Defined Subgroup Analysis in the RE-DUAL PCI Randomized Trial).

被引：0
|
作者：
Nicolau, Jose C. [1 ]
Bhatt, Deepak L. [2 ]
Hohnloser, Stefan H. [3 ]
Kimura, Takeshi [4 ]
Lip, Gregory Y. [5 ]
Meide, Corinna [6 ]
Nordaby, Matias [7 ]
Oldgren, Jonas [8 ,9 ]
Steg, Philippe [10 ]
ten Berg, Jurrien M. [11 ]
Cannon, Christopher [12 ,13 ]
机构：
[1] Univ Sao Paulo, Fac Med, Inst Coracao InCor, Hosp Clin HCFMUSP, Sao Paulo, SP, Brazil
[2] Brigham & Womens Hosp, Boston & Harvard Med Sch, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA
[3] Goethe Univ Frankfurt, Div Cardiol, Dept Med, Frankfurt, Germany
[4] Kyoto Univ, Dept Cardiovasc Med, Kyoto, Japan
[5] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England
[6] HMS Analyt Software GmbH, Software, Weimar, Lahn, Germany
[7] Boehringer Ingelheim Int GmbH, TA CardioMetab, Ingelheim, Germany
[8] Uppsala Univ, Uppsala Clin Rsch Ctr, Uppsala, Sweden
[9] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[10] Hop Bichat Claude Bernard, Dept Cardiol, AP HP, Paris, France
[11] St Antonius Hosp, Dept Cardiol, Nieuwegein, Netherlands
[12] Brigham & Womens Hosp, Div Cardiol, Heart & Vasc Ctr, Boston, MA 02115 USA
[13] Harvard Med Sch, Boston, MA 02115 USA
来源：
CIRCULATION | 2018年 / 138卷
关键词：
Antithrombotic therapy; Atrial fibrillation; Coronary artery disease; Dabigatran; Percutaneous coronary intervention (PCI);
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A11775
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI
    Costa, Francesco
    Valgimigli, Marco
    Steg, Philippe Gabriel
    Bhatt, Deepak L.
    Hohnloser, Stefan H.
    Ten Berg, Jurrien M.
    Miede, Corinna
    Nordaby, Matias
    Lip, Gregory Y. H.
    Oldgren, Jonas
    Cannon, Christopher P.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (03) : 216 - 226
  • [32] Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease
    Lopes, Renato D.
    Rao, Meena
    Simon, DaJuanicia N.
    Thomas, Laine
    Ansell, Jack
    Fonarow, Gregg C.
    Gersh, Bernard J.
    Go, Alan S.
    Hylek, Elaine M.
    Kowey, Peter
    Piccini, Jonathan P.
    Singer, Daniel E.
    Chang, Paul
    Peterson, Eric D.
    Mahaffey, Kenneth W.
    AMERICAN JOURNAL OF MEDICINE, 2016, 129 (06): : 592 - U197
  • [33] High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI
    De Caterina, R.
    Lopez Sendon, J. L.
    Mehta, S.
    Opolski, G.
    Oldgren, J.
    Steg, P. G.
    Hohnloser, S.
    Lip, G. Y. H.
    Kimura, T.
    Nordaby, M.
    Kleine, E.
    Ten Berg, J. M.
    Bhatt, D. L.
    Cannon, C.
    EUROPEAN HEART JOURNAL, 2018, 39 : 458 - 458
  • [34] Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied, D.
    Brachmann, J.
    Darius, H.
    Frey, N.
    Katus, H. A.
    Rottbauer, W.
    Schaefer, A.
    Thiele, H.
    Bode, C.
    Zeymer, Uwe
    CLINICAL RESEARCH IN CARDIOLOGY, 2018, 107 (07) : 533 - 538
  • [35] Dual Versus Triple Antithrombotic Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation: An Updated Meta-Analysis
    Goel, Sunny
    Pasam, Ravi Teja
    Sharma, Abhishek
    Gidwani, Umesh
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2020, 21 (02) : 239 - 241
  • [36] Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    D. Duerschmied
    J. Brachmann
    H. Darius
    N. Frey
    H. A. Katus
    W. Rottbauer
    A. Schäfer
    H. Thiele
    C. Bode
    Uwe Zeymer
    Clinical Research in Cardiology, 2018, 107 : 533 - 538
  • [37] Evaluation of Antithrombotic Strategies Before and After the First Month of Therapy: Landmark Analysis of the RE-DUAL PCI Trial
    Bhatt, Deepak
    Steg, Philippe Gabriel
    Oldgren, Jonas
    Maeng, Michael
    Zeymer, Uwe
    Halvorsen, Sigrun
    Hohnloser, Stefan
    Lip, Gregory
    Kimura, Takeshi
    Nordaby, Matias
    Corinna, Miede
    Ten Berg, Jurrien
    Cannon, Christopher
    Peterson, Benjamin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (17) : B24 - B25
  • [38] COST EFFECTIVENESS OF DUAL VS. TRIPLE THERAPY IN MANAGEMENT OF ATRIAL FIBRILLATION WITH PERCUTANEOUS CORONARY INTERVENTION
    Kim, J.
    Park, T. J.
    Devine, B.
    VALUE IN HEALTH, 2023, 26 (06) : S79 - S79
  • [39] Dual vs. Triple Antithrombotic Therapy After Coronary Stenting in Patients With Non-Valvular Atrial Fibrillation
    Mennuni, Marco G.
    Kherada, Nisharahmed
    Halperin, Jonathan
    Theodoropoulos, Kleanthis
    Sartori, Samantha
    Midulla, Danielle
    Thapi, Roja
    Hasan, Choudhury
    Moreno, Pedro
    Krishnan, Prakash
    Kovacic, Jason
    Baber, Usman
    Pyo, Robert
    Sweeny, Joseph
    Dangas, George D.
    Mehran, Roxana
    Sharma, Samin
    Kini, Annapoorna
    CIRCULATION, 2013, 128 (22)
  • [40] Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy
    Berteotti, M.
    Gori, A. M.
    Giusti, B.
    Fortini, A.
    Grossi, G.
    Ciardetti, N.
    Migliorini, A.
    Lotti, E.
    Valenti, R.
    Di Mario, C.
    Marchionni, N.
    Marcucci, R.
    EUROPEAN HEART JOURNAL, 2023, 44
12345